- Home
- ONC vs DXCM Comparison
ONC vs DXCM Comparison
Compare ONC & DXCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONC
- DXCM
- Stock Information
- Founded
- ONC 2010
- DXCM 1999
- Country
- ONC Switzerland
- DXCM United States
- Employees
- ONC N/A
- DXCM N/A
- Industry
- ONC Biotechnology: Pharmaceutical Preparations
- DXCM Medical/Dental Instruments
- Sector
- ONC Health Care
- DXCM Health Care
- Exchange
- ONC Nasdaq
- DXCM Nasdaq
- Market Cap
- ONC 31.5B
- DXCM 34.1B
- IPO Year
- ONC N/A
- DXCM 2005
- Fundamental
- Price
- ONC $299.01
- DXCM $79.28
- Analyst Decision
- ONC Strong Buy
- DXCM Strong Buy
- Analyst Count
- ONC 9
- DXCM 19
- Target Price
- ONC $332.44
- DXCM $99.89
- AVG Volume (30 Days)
- ONC 411.4K
- DXCM 3.1M
- Earning Date
- ONC 08-06-2025
- DXCM 07-30-2025
- Dividend Yield
- ONC N/A
- DXCM N/A
- EPS Growth
- ONC N/A
- DXCM N/A
- EPS
- ONC N/A
- DXCM 1.43
- Revenue
- ONC $4,175,868,000.00
- DXCM $4,300,800,000.00
- Revenue This Year
- ONC $865.19
- DXCM $16.74
- Revenue Next Year
- ONC $21.12
- DXCM $15.42
- P/E Ratio
- ONC N/A
- DXCM $55.44
- Revenue Growth
- ONC 51.16
- DXCM 9.30
- 52 Week Low
- ONC $155.75
- DXCM $57.52
- 52 Week High
- ONC $308.87
- DXCM $93.25
- Technical
- Relative Strength Index (RSI)
- ONC N/A
- DXCM 35.30
- Support Level
- ONC N/A
- DXCM $83.23
- Resistance Level
- ONC N/A
- DXCM $89.98
- Average True Range (ATR)
- ONC 0.00
- DXCM 1.91
- MACD
- ONC 0.00
- DXCM -0.54
- Stochastic Oscillator
- ONC 0.00
- DXCM 3.17
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
About DXCM DexCom Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.